CA1281849C - Solubilization of protein aggregates - Google Patents
Solubilization of protein aggregatesInfo
- Publication number
- CA1281849C CA1281849C CA000524987A CA524987A CA1281849C CA 1281849 C CA1281849 C CA 1281849C CA 000524987 A CA000524987 A CA 000524987A CA 524987 A CA524987 A CA 524987A CA 1281849 C CA1281849 C CA 1281849C
- Authority
- CA
- Canada
- Prior art keywords
- protein
- cationic surfactant
- cations
- insoluble
- source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 67
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 65
- 238000005063 solubilization Methods 0.000 title claims abstract description 15
- 230000007928 solubilization Effects 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 43
- 239000003093 cationic surfactant Substances 0.000 claims abstract description 32
- -1 cetyl trimethylammonium cations Chemical class 0.000 claims abstract description 18
- 238000011084 recovery Methods 0.000 claims abstract description 13
- 239000003495 polar organic solvent Substances 0.000 claims abstract description 8
- 239000004094 surface-active agent Substances 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 5
- 230000004048 modification Effects 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims abstract description 5
- 229960004830 cetylpyridinium Drugs 0.000 claims abstract description 4
- 150000001768 cations Chemical class 0.000 claims abstract 6
- 210000003000 inclusion body Anatomy 0.000 claims description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 15
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical group [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 239000000122 growth hormone Substances 0.000 claims description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 239000004202 carbamide Substances 0.000 claims description 7
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 7
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 7
- 239000000693 micelle Substances 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 150000003856 quaternary ammonium compounds Chemical group 0.000 claims description 3
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 claims 1
- 239000008188 pellet Substances 0.000 description 10
- 102000018997 Growth Hormone Human genes 0.000 description 7
- 108010051696 Growth Hormone Proteins 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000702626 Infectious bursal disease virus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 1
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019846 buffering salt Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical class [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPH3818 | 1985-12-11 | ||
| AUPH381885 | 1985-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1281849C true CA1281849C (en) | 1991-03-19 |
Family
ID=3771404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000524987A Expired - Lifetime CA1281849C (en) | 1985-12-11 | 1986-12-10 | Solubilization of protein aggregates |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4797474A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0226448B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPH0660198B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN86108729A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE76878T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU597924B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA1281849C (cg-RX-API-DMAC7.html) |
| DE (1) | DE3685562T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK171331B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2032194T3 (cg-RX-API-DMAC7.html) |
| GR (1) | GR3004903T3 (cg-RX-API-DMAC7.html) |
| MY (1) | MY101204A (cg-RX-API-DMAC7.html) |
| NO (1) | NO864990L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ218586A (cg-RX-API-DMAC7.html) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037644A (en) * | 1986-10-27 | 1991-08-06 | Cetus Corporation | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes |
| AU612133B2 (en) * | 1987-02-20 | 1991-07-04 | Natinco Nv | Production of proteins in active forms |
| CA1305285C (en) * | 1987-04-21 | 1992-07-14 | Malcolm Roy Brandon | Production of proteins in active forms |
| US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| US5654176A (en) * | 1987-05-28 | 1997-08-05 | Amrad Corporation Limited | Fusion proteins containing glutathione-s-transferase |
| EP0295859B1 (en) * | 1987-06-15 | 1994-11-17 | Southern Cross Biotech Pty.Ltd. | Production of proteins in active forms |
| AU609824B2 (en) * | 1987-06-15 | 1991-05-09 | Southern Cross Biotech Pty Ltd. | Production of proteins in active forms |
| US5266205A (en) * | 1988-02-04 | 1993-11-30 | Battelle Memorial Institute | Supercritical fluid reverse micelle separation |
| US5637566A (en) * | 1988-08-24 | 1997-06-10 | Southern Cross Biotech Pty. Ltd. | Method of improving carcass quality by administering growth hormone |
| US5136027A (en) * | 1989-05-02 | 1992-08-04 | Abbott Laboratories | Method for renaturing proteins in the presence of alkyl sulfate detergents |
| DE69122280T2 (de) * | 1990-03-01 | 1997-04-24 | Hewlett Packard Co | Minimierung von Eluatbandbreiten in der Flüssigchromatographie |
| US5530100A (en) * | 1990-05-07 | 1996-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Methods for purification of recombinantly produced proteins |
| EP0529201B1 (en) * | 1991-08-26 | 1997-09-24 | Hewlett-Packard Company | Chromatographic method with micellar on-column enrichment |
| US5252216A (en) * | 1992-03-24 | 1993-10-12 | Smithkline Beecham Corporation | Protein purification |
| JP2000516210A (ja) | 1996-07-12 | 2000-12-05 | ロイコサイト，インコーポレーテッド | ケモカインレセプターアンタゴニストとその使用方法 |
| ZA9711733B (en) | 1996-12-31 | 1998-07-01 | Monsanto Co | Method for solubilization and naturation of somatotropins |
| US20020052026A1 (en) * | 1997-10-08 | 2002-05-02 | Steven M. Vicik | Methods of refolding proteins |
| EP2158923B1 (en) | 1998-08-06 | 2013-02-27 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
| JP2006507818A (ja) * | 2002-11-01 | 2006-03-09 | プロメガ コーポレイション | 細胞溶解のための組成物、使用方法、装置およびキット |
| DE10309691B4 (de) | 2003-02-28 | 2018-10-04 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | Gewinnung von löslichen Proteinen aus der Biomasse rekombinanter Mikroorganismen |
| US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| US20080159976A1 (en) * | 2005-04-11 | 2008-07-03 | Jacob Hartman | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| NZ562292A (en) | 2005-04-11 | 2009-11-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| TWI418564B (zh) * | 2005-04-11 | 2013-12-11 | Savient Pharmaceuticals Inc | 利用陽離子界面活性劑之蛋白質純化 |
| SG2014009484A (en) * | 2005-04-11 | 2014-05-29 | Savient Pharmaceuticals Inc | A variant form of urate oxidase and use thereof |
| US20090081122A1 (en) * | 2005-05-23 | 2009-03-26 | Universite De Geneve | Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant |
| US20100221747A1 (en) * | 2005-12-14 | 2010-09-02 | Denka Seiken Co., Ltd. | Immunochromatography detection of multidrug-resistant staphylococcus and diagnostic kit |
| JP5033177B2 (ja) * | 2006-04-12 | 2012-09-26 | サビエント ファーマセウティカルズ インク． | 陽イオン界面活性剤によるタンパク質の精製 |
| EP2074223A4 (en) * | 2006-09-15 | 2010-03-10 | Foldrx Pharmaceuticals Inc | TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS |
| US9706787B2 (en) * | 2007-10-05 | 2017-07-18 | Advance International Inc. | Systems and methods for deriving protein powder |
| US8663725B2 (en) * | 2007-10-05 | 2014-03-04 | Advance International Inc. | Method for deriving a high-protein powder/ omega 3 oil and double distilled water from any kind of fish or animal ( protein) |
| NZ597089A (en) | 2009-06-25 | 2014-05-30 | Savient Pharmaceuticals Inc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| CN104507953B (zh) * | 2012-05-31 | 2018-05-18 | 新加坡科技研究局 | 通过用正电性有机添加剂处理来降低蛋白质制剂中蛋白质-污染物复合物和聚集物水平的方法 |
| US9826757B2 (en) | 2013-03-15 | 2017-11-28 | Advance International Inc. | Automated method and system for recovering protein powder meal, pure omega 3 oil and purified distilled water from animal tissue |
| WO2014192877A1 (ja) * | 2013-05-29 | 2014-12-04 | Jsr株式会社 | 洗浄用組成物、タンパク質精製方法、及びタンパク質 |
| KR20160127087A (ko) * | 2014-02-27 | 2016-11-02 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 알킬 양이온들로의 처리에 의한 단백질 제제들 내의 크로마틴 함량을 감소시키기 위한 방법들 |
| CA2920789C (en) | 2015-06-04 | 2021-05-18 | Advance International, Inc. | Improved methods and systems for recovering protein powder and natural omega-3 oil from animal tissue |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| WO2018089808A1 (en) | 2016-11-11 | 2018-05-17 | Horizon Pharma Rheumatology Llc | Combination therapies of prednisone and uricase molecules and uses thereof |
| WO2019103106A1 (ja) * | 2017-11-22 | 2019-05-31 | 学校法人東京薬科大学 | 凝集タンパク質の再生剤およびこれを用いた凝集タンパク質の再生方法 |
| WO2020160322A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple) |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2829089A1 (de) * | 1977-07-13 | 1979-02-01 | Sandoz Ag | Subunit-vakzine |
| US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
| US4659568A (en) * | 1985-02-27 | 1987-04-21 | American Cyanamid Company | Process for solubilization, purification and characterization of protein from insoluble protein aggregates or complexes and compositions of matter therefrom |
| US4656255A (en) * | 1985-09-09 | 1987-04-07 | International Minerals & Chemical Corp. | Protein recovery |
| AU612117B2 (en) * | 1986-07-28 | 1991-07-04 | Allied Corporation | Sulfonate benzotriazoles and their use in polyamide |
-
1985
- 1985-12-11 AU AU66874/86A patent/AU597924B2/en not_active Expired
-
1986
- 1986-12-09 US US06/939,578 patent/US4797474A/en not_active Expired - Lifetime
- 1986-12-10 ES ES198686309603T patent/ES2032194T3/es not_active Expired - Lifetime
- 1986-12-10 EP EP86309603A patent/EP0226448B1/en not_active Expired - Lifetime
- 1986-12-10 NO NO864990A patent/NO864990L/no unknown
- 1986-12-10 NZ NZ218586A patent/NZ218586A/xx unknown
- 1986-12-10 DK DK592186A patent/DK171331B1/da not_active IP Right Cessation
- 1986-12-10 DE DE8686309603T patent/DE3685562T2/de not_active Expired - Lifetime
- 1986-12-10 CA CA000524987A patent/CA1281849C/en not_active Expired - Lifetime
- 1986-12-10 AT AT86309603T patent/ATE76878T1/de not_active IP Right Cessation
- 1986-12-11 JP JP61295714A patent/JPH0660198B2/ja not_active Expired - Fee Related
- 1986-12-11 MY MYPI86000197A patent/MY101204A/en unknown
- 1986-12-11 CN CN198686108729A patent/CN86108729A/zh active Pending
-
1992
- 1992-06-11 GR GR920401248T patent/GR3004903T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0226448B1 (en) | 1992-06-03 |
| ES2032194T3 (es) | 1993-01-16 |
| NZ218586A (en) | 1989-07-27 |
| DK592186D0 (da) | 1986-12-10 |
| US4797474A (en) | 1989-01-10 |
| DK171331B1 (da) | 1996-09-09 |
| DE3685562D1 (de) | 1992-07-09 |
| EP0226448A3 (en) | 1989-01-11 |
| AU6687486A (en) | 1987-06-18 |
| DE3685562T2 (de) | 1992-12-24 |
| NO864990L (no) | 1987-06-12 |
| MY101204A (en) | 1991-08-17 |
| CN86108729A (zh) | 1987-10-21 |
| JPH0660198B2 (ja) | 1994-08-10 |
| EP0226448A2 (en) | 1987-06-24 |
| GR3004903T3 (cg-RX-API-DMAC7.html) | 1993-04-28 |
| AU597924B2 (en) | 1990-06-14 |
| DK592186A (da) | 1987-06-12 |
| JPS62223192A (ja) | 1987-10-01 |
| ATE76878T1 (de) | 1992-06-15 |
| NO864990D0 (no) | 1986-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1281849C (en) | Solubilization of protein aggregates | |
| CA1305284C (en) | Method for the recovery of cellular proteins in active form | |
| EP0279619B1 (en) | Production of proteins in active forms | |
| CA1267497A (en) | Protein recovery | |
| JPS59161321A (ja) | 沈澱異種蛋白質の精製及び活性化法 | |
| Cardamone et al. | Comparing the refolding and reoxidation of recombinant porcine growth hormone from a urea denatured state and from Escherichia coli inclusion bodies | |
| US5008377A (en) | Production of proteins in active forms | |
| CN1290299A (zh) | 人胰岛素原的制备方法 | |
| PL209954B1 (pl) | Sposób oczyszczania białek interferonu i jego zastosowanie | |
| CA2699529A1 (en) | Procedures for the separation of recombinant proteins in aqueous two-phase systems | |
| KR0178274B1 (ko) | 재조합 소마토트로핀의 회수방법 | |
| EP0295859A2 (en) | Production of proteins in active forms | |
| Liu et al. | Derivatization of peptides and small proteins for improved identification and detection in capillary zone electrophoresis (CZE) | |
| CA1340586C (en) | Process for recovering microbially produced interferon-beta | |
| Chatterjee et al. | Studies on Rabbit Reticulocyte Ribosomes, II. Separation of the Ribosomal Proteins by Two-dimensional Electrophoresis | |
| US7935798B2 (en) | Method for the extraction of intracellular proteins from a fermentation broth | |
| AU607988B2 (en) | Production of proteins in active forms | |
| AU4143097A (en) | A process for purifying apolipoproteins and a composition for use in the process | |
| WO1999061474A1 (en) | Purified human activin and process for producing the same | |
| Wuethrich et al. | Peptide building blocks from bacteriorhodopsin: isolation and physicochemical characterization of two individual transmembrane segments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed | ||
| MKEC | Expiry (correction) |
Effective date: 20121205 |